pyrroles has been researched along with ah 111585 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beer, AJ; Schwaiger, M | 1 |
| Allen, L; Barnett, J; Battle, MR; Goggi, JL; Morrison, MS | 1 |
2 other study(ies) available for pyrroles and ah 111585
| Article | Year |
|---|---|
PET of αvbeta3-integrin and αvbeta5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time?
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Peptides; Polyethylene Glycols; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Vitronectin; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2011 |
Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVbeta3-integrin and αV beta5-integrin imaging agent.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Glioblastoma; Humans; Indoles; Integrin alphaVbeta3; Male; Mice; Mice, Nude; Peptides; Polyethylene Glycols; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Vitronectin; Reproducibility of Results; Sensitivity and Specificity; Sunitinib | 2011 |